Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.

Abstract

Thalidomide has shown its efficacy in the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT) patients. We hypothetize that, owing to its anti-inflammatory/antiangiogenic/vascular growth maturation properties, thalidomide should be useful in the prophylaxis and therapy of HHT patients presenting with initial lung involvement.

• Authors: Alexis Lacout, Pierre Yves Marcy, Mostafa El Hajjam, Pascal Lacombe
• Journal: Medical hypotheses (Med Hypotheses) Vol. 80 Issue 5 Pg. 587-8 (May 2013) ISSN: 1532-2777 [Electronic] United States
• PMID: 23452644 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Thalidomide

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Arteriovenous Fistula (drug therapy, etiology, physiopathology)
• Humans
• Models, Biological
• Neovascularization, Pathologic (etiology, physiopathology, prevention & control)
• Pulmonary Artery (abnormalities, physiopathology)
• Pulmonary Veins (abnormalities, physiopathology)
• Telangiectasia, Hereditary Hemorrhagic (complications, drug therapy, physiopathology)
• Thalidomide (therapeutic use)